Anbalcabtagene Autoleucel: First Approval
Author:
- 7 September 2026
- journal article
- other
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 30 (6) , 999-1002
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trialBlood, 2026
- Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaCancer Research and Treatment, 2025
- Anti‐PD‐1 therapy can possibly reverse CAR T cells exhaustion in DLBCLBritish Journal of Haematology, 2023
- PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cellsMolecular Therapy, 2022
- Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2021